In vivo drug testing

screening of new anti-cancer agents

Our GLIOscreen in vivo testing services offer the possibility to test agents in subcutaneous and orthotopic xenograft tumor models. Diversity in molecular subtype, survival and growth patterns of intracranial tumors allows validation of predicted response in a more clinically-relevant setting. Moreover, delivery and micro-environmental aspects are incorporated in this model. Luciferase-expressing xenograft models are available allowing close monitoring of intracranial growth and response to treatment by in vivo bioluminescence analysis.